Validation of the Chinese version of EORTC QLQ-BM22 in patients with bone metastases

Support Care Cancer. 2016 Mar;24(3):1019-24. doi: 10.1007/s00520-015-2870-y. Epub 2015 Aug 6.

Abstract

Purpose: Our aim is to test the validity, reliability, and acceptability of the Chinese version of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Bone Metastases 22 (EORTC QLQ-BM22) module to assess health-related quality of life (HRQOL) in patients with bone metastases in China.

Methods: Patients with histological confirmation of malignancy and bone metastases from Tianjin Cancer Institution and Hospital from June 2013 to April 2014 were enrolled in this study. All patients self-administered the EORTC QLQ-BM22 and the EORTC QLQ-C30. The Karnofsky Performance Scale (KPS) was performed to evaluate scores. The reliability and validity tests of the questionnaires were based on Cronbach's α coefficients, Pearson correlation test, and Wilcoxon rank sum nonparametric test.

Results: Internal consistency reliabilities of all the four scales were acceptable. Scales measuring similar HRQOL aspects were found to correlate with one another between EORTC QLQ-BM22 and EORTC QLQ-C30, but differences still existed. Significant differences were demonstrated in the scores of all four subscales of the QLQ-BM22 between the two KPS subgroups (KPS ≤ 80; KPS > 80). Meanwhile, the compliance for item completion of the QLQ-BM22 was satisfactory.

Conclusions: The Chinese version of EORTC QLQ-BM22 is a reliable and valid instrument, which is appropriate for measuring the HRQOL of patients with bone metastases in China.

Keywords: Bone metastases; EORTC QLQ-BM22; Health-related quality of life; Validation.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Asian People
  • Bone Density Conservation Agents / therapeutic use*
  • Bone Neoplasms / secondary*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Patient Compliance
  • Quality of Life*
  • Surveys and Questionnaires
  • Validation Studies as Topic
  • Young Adult

Substances

  • Bone Density Conservation Agents